Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
Revolution Medicines (Nasdaq: RVMD) has announced a forthcoming investor webcast to provide clinical updates on their RAS(ON) inhibitor portfolio. The event, focused on their targeted therapies for RAS-addicted cancers, is scheduled for December 2, 2024, at 8:00 a.m. Eastern Time. The webcast will be accessible online, with a replay available on the company's website's Events & Presentations page for at least 14 days after the live event.
Revolution Medicines (Nasdaq: RVMD) ha annunciato un prossimo webcast per gli investitori per fornire aggiornamenti clinici sul loro portafoglio di inibitori RAS(ON). L'evento, incentrato sulle terapie mirate per i tumori dipendenti da RAS, è programmato per il 2 dicembre 2024, alle 8:00 ora locale orientale. Il webcast sarà accessibile online, con una registrazione disponibile nella pagina Eventi e Presentazioni del sito web dell'azienda per almeno 14 giorni dopo l'evento dal vivo.
Revolution Medicines (Nasdaq: RVMD) ha anunciado un próximo webcast para inversores que proporcionará actualizaciones clínicas sobre su portafolio de inhibidores RAS(ON). El evento, centrado en sus terapias dirigidas para cánceres adictos a RAS, está programado para el 2 de diciembre de 2024, a las 8:00 a.m. hora del Este. El webcast estará disponible en línea, con una repetición accesible en la página de Eventos y Presentaciones del sitio web de la compañía durante al menos 14 días después del evento en vivo.
Revolution Medicines (Nasdaq: RVMD)는 RAS(ON) 억제제 포트폴리오에 대한 임상 업데이트를 제공하기 위한 투자자 웹캐스트를 곧 개최한다고 발표했습니다. RAS 의존 암을 위한 표적 치료에 중점을 둔 이 행사는 2024년 12월 2일 오전 8시 동부 표준시로 예정되어 있습니다. 웹캐스트는 온라인에서 접근 가능하며, 생중계 이후 최소 14일 동안 회사 웹사이트의 이벤트 및 발표 페이지에서 다시 시청할 수 있습니다.
Revolution Medicines (Nasdaq: RVMD) a annoncé un prochain webcast pour les investisseurs afin de fournir des mises à jour cliniques sur son portefeuille d'inhibiteurs RAS(ON). L'événement, axé sur ses thérapies ciblées pour les cancers dépendants du RAS, est programmé pour le 2 décembre 2024 à 8h00, heure de l'Est. Le webcast sera accessible en ligne, avec un replay disponible sur la page Événements et Présentations du site de l'entreprise pendant au moins 14 jours après l'événement en direct.
Revolution Medicines (Nasdaq: RVMD) hat ein bevorstehendes Investoren-Webcast angekündigt, um klinische Updates zu ihrem RAS(ON)-Inhibitoren-Portfolio zu geben. Die Veranstaltung, die sich auf ihre zielgerichteten Therapien für RAS-abhängige Krebserkrankungen konzentriert, ist für den 2. Dezember 2024 um 8:00 Uhr Eastern Time geplant. Der Webcast wird online zugänglich sein, und eine Wiederholung wird auf der Seite 'Veranstaltungen und Präsentationen' der Unternehmenswebsite für mindestens 14 Tage nach der Live-Veranstaltung verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.
The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click here. An archived replay will be available on the “Events & Presentations” page of the Revolution Medicines website at https://ir.revmed.com/events-and-presentations for at least 14 days following the live event.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
FAQ
When is Revolution Medicines (RVMD) hosting its RAS(ON) inhibitor clinical update webcast?
How long will the replay of RVMD's December 2024 clinical update webcast be available?
What is the focus of Revolution Medicines' (RVMD) December 2024 webcast?
Where can investors access RVMD's December 2024 clinical update webcast?
